Literature DB >> 22514377

Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

S K Nath1, G A Foster, L A Mandell, C Rotstein.   

Abstract

The effect of serum albumin on the antimicrobial activity of ceftriaxone, cefotaxime, and a 1:1 ratio of cefotaxime and its desacetyl metabolite against nonpseudomonal Gram-negative bacilli was determined. Antimicrobial activity of drugs was evaluated by measuring minimum inhibitory (mic) and bactericidal (mbc) concentrations in broth with and without human serum albumin. The analysis of logarithmically transformed mean mics and mbcs showed that there was a highly significant interaction between drug and serum albumin (P<0.0001). The inhibitory and bactericidal activities were greatest for cefotaxime followed by cefotaxime/desacetylcefotaxime and ceftriaxone (P<0.01). Time-kill kinetics demonstrated that ceftriaxone was less bactericidal than cefotaxime in broth with albumin. On the basis of these results it was concluded that the in vitro antimicrobial activity of ceftriaxone compared with that of cefotaxime was significantly diminished in the presence of serum albumin.

Entities:  

Keywords:  Antimicrobial activity; Cefotaxime; Ceftriaxone; Serum albumin

Year:  1995        PMID: 22514377      PMCID: PMC3327896          DOI: 10.1155/1995/617610

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  31 in total

1.  Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics.

Authors:  S Tawara; S Matsumoto; T Kamimura; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  The importance of the geometric mean MIC.

Authors:  B I Davies
Journal:  J Antimicrob Chemother       Date:  1990-03       Impact factor: 5.790

3.  Theory and practical impact of binding of antimicrobials to serum proteins and tissue.

Authors:  W A Craig; B Suh
Journal:  Scand J Infect Dis Suppl       Date:  1978

4.  Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

5.  Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. I.

Authors:  R Wise
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

6.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

Review 7.  Third generation cephalosporins: safety profiles after 10 years of clinical use.

Authors:  H C Neu
Journal:  J Clin Pharmacol       Date:  1990-05       Impact factor: 3.126

Review 8.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

9.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

10.  Extravascular penetration of highly protein-bound flucloxacillin.

Authors:  T Bergan; A Engeset; W Olszewski; N Ostby; R Solberg
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

View more
  2 in total

Review 1.  Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

Authors:  Alireza FakhriRavari; Brenda Simiyu; Taylor Morrisette; Yewande Dayo; Jacinda C Abdul-Mutakabbir
Journal:  Drugs Context       Date:  2022-01-20

2.  CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales.

Authors:  Amy J Mathers; James S Lewis
Journal:  JAC Antimicrob Resist       Date:  2021-05-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.